
Opinion|Videos|December 20, 2024
Emerging BTKi Combinations in CLL: A New Frontier of Treatment Options
Panelists discuss how, coming into ASH 2024, the largest unmet needs in the treatment and management of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) include improving outcomes for treatment-naive patients, with a focus on emerging Bruton tyrosine kinase inhibitor (BTKi) regimens such as acalabrutinib plus venetoclax, pirtobrutinib plus venetoclax, and zanubrutinib combinations.
Advertisement
Video content above is prompted by the following:
- Coming into ASH 2024, what would you consider to be the largest unmet needs in the treatment and management of CLL and MCL?
- Provide an overview of the following emerging BTKi treatment regimens in treatment-naive patients with CLL.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement